Shanghai Serum Bio-Technology Co., Ltd. (SHA:688163)
35.72
+0.17 (0.48%)
Sep 1, 2026, 4:00 PM EDT
SHA:688163 Revenue
Shanghai Serum Bio-Technology had revenue of 77.12M CNY in the quarter ending June 30, 2026, with 2.55% growth. This brings the company's revenue in the last twelve months to 199.60M, up 0.97% year-over-year. In the year 2025, Shanghai Serum Bio-Technology had annual revenue of 196.21M with 0.66% growth.
Revenue (ttm)
199.60M
Revenue Growth
+0.97%
P/S Ratio
19.37
Revenue / Employee
604.84K
Employees
330
Market Cap
3.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 196.21M | 1.29M | 0.66% |
| Dec 31, 2024 | 194.92M | 4.77M | 2.51% |
| Dec 31, 2023 | 190.14M | 15.92M | 9.14% |
| Dec 31, 2022 | 174.22M | -34.47M | -16.52% |
| Dec 31, 2021 | 208.69M | 23.13M | 12.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 3.00B |
| Hefei Lifeon Pharmaceutical | 1.51B |
| Xiangxue Pharmaceutical | 1.48B |
| Kexing Biopharm | 1.44B |
| Pulike Biological Engineering | 1.02B |
| Beijing Bohui Innovation Biotechnology Group | 816.14M |
| Assure Tech (Hangzhou) | 407.16M |
| Beijing Scitop Bio-tech | 372.08M |